Modern understanding and advances in the diagnosis and treatment of obesity

doi:10.16139/j.1007-9610.2025.03.01

Abstract

Abstract:

As a multifactorial chronic metabolic disorder with complex causes and serious health risks, obesity has drawn significant societal and medical attention. This article systematically reviewed the latest advancements in the clinical diagnosis and treatment of obesity. A disease-centered diagnosis and treatment concept has been proposed, which combines BMI and introduces a brand-new clinical diagnosis and treatment standard centered on fat content and functional disorders, such as new diagnostic markers like adipose tissue distribution, visceral adiposity, and waist-to-height ratio, to conduct a comprehensive assessment and lifespan management of patients. In recent years, novel biomarkers and artificial intelligence (AI)-assisted diagnosis have provided new tools for the diagnosis and treatment of obesity. In terms of treatment, combined therapy based on lifestyle and behavioral intervention has been widely recognized. The advent of new weight-loss drugs, such as glucagon-like peptide-1(GLP-1), minimally invasive techniques such as endoscopic sleeve gastrectomy(ESG), which reduced surgical risks, have provided possibilities for the treatment of obesity. The current concept of obesity management has become increasingly mature, feasible, and standardized. The construction principles of a weight management center, characterized by centralized management and individualized treatment, ensure the long-term stability of body weight and promote a healthy quality of life for patients with obesity.

Key words: Obesity, Weight-loss drugs, Bariatric surgery, Artificial intelligence (AI)-assisted therapy, Centralized management

CLC Number:

R589.2

BU Le, TONG Chuyan, QU Shen. Modern understanding and advances in the diagnosis and treatment of obesity[J]. Journal of Surgery Concepts & Practice, 2025, 30(03): 185-191.

References 44

[1]	RUBINO F, CUMMINGS D E, ECKEL R H, et al. Definition and diagnostic criteria of clinical obesity[J]. Lancet Diabetes Endocrinol, 2025, 13(3):221-262.
[2]	CIFUENTES L, GHUSN W, FERIS F, et al. Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study[J]. EClinicalMedicine, 2023,58,101923.
[3]	LIN Z W, FENG W H, LIU Y J, et al. Machine learning to identify metabolic subtypes of obesity: a multi-center study[J]. Front Endocrinol (Lausanne), 2021,12:713592.
[4]	ACOSTA A, CAMILLERI M, ABU DAYYEH B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic[J]. Obesity(Silver Spring), 2021, 29(4):662-671.
[5]	中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南(2024版)[J]. 中华内分泌代谢杂志, 2024, 40(7):545-564.
	Chinese Medical Association of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications (2024 version)[J]. Chin J Endocrinol Metabol, 2024, 40(7):545-564.
[6]	MEHTA N H, HUEY S L, KURIYAN R, et al. Potential mechanisms of precision nutrition-based interventions for managing obesity[J]. Adv Nutr, 2024, 15(3):100186.
[7]	DEEHAN E C, MOCANU V, MADSEN K L. Effects of dietary fibre on metabolic health and obesity[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(5):301-318. doi: 10.1038/s41575-023-00891-z pmid: 38326443
[8]	LIU H Y, GUO X, JIANG K X, et al. Dietary polyphenols regulate appetite mechanism via gut-brain axis and gut homeostasis[J]. Food Chem, 2024,446:138739.
[9]	LIU D Y, HUANG Y, HUANG C, et al. Calorie restriction with or without time-restricted eating in weight loss[J]. N Engl J Med, 2022, 386(16):1495-1504.
[10]	HEERMAN W J, ROTHMAN R L, SANDERS L M, et al. A digital health behavior intervention to prevent childhood obesity: the greenlight plus randomized clinical trial[J]. JAMA, 2024, 332(24):2068-2080. doi: 10.1001/jama.2024.22362 pmid: 39489149
[11]	Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study[J]. Lancet Diabetes Endocrinol, 2015, 3(11):866-875.
[12]	LEAN M E, LESLIE W S, BARNES A C, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial[J]. Lancet, 2018, 391(10120):541-551. doi: S0140-6736(17)33102-1 pmid: 29221645
[13]	HENRIKSEN A, HAUGEN MIKALSEN M, WOLDAREGAY A Z, et al. Using fitness trackers and smartwatches to measure physical activity in research: analysis of consumer wrist-worn wearables[J]. J Med Internet Res, 2018, 20(3):e110.
[14]	MU Y M, BAO X L, ELIASCHEWITZ F G, et al. Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2024, 12(3):184-195.
[15]	RODRIGUEZ P J, GOODWIN CARTWRIGHT B M, GRATZL S, et al. Semaglutide vs. tirzepatide for weight loss in adults with overweight or obesity[J]. JAMA Intern Med, 2024, 184(9):1056-1064.
[16]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5):729-732.
	ZHANG L Y, DU H Z, PAN H. Progress in drug therapy for hypothalamic obesity[J]. Basic Clin Med, 2024, 44(5):729-732.
[17]	WANG Y, BERNARD A, COMBLAIN F, et al. Melanocortin 4 receptor signals at the neuronal primary cilium to control food intake and body weight[J]. J Clin Invest, 2021, 131(9):e142064.
[18]	YEO G S H, CHAO D H M, SIEGERT A M, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy[J]. Mol Metab, 2021,48:101206.
[19]	MIAO Y Q, FAN K Y, PENG X J, et al. Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma[J]. Front Endocrinol (Lausanne), 2023,14:1241145.
[20]	HSIA D S, GOSSELIN N H, WILLIAMS J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity[J]. Diabetes Obes Metab, 2020, 22(4):480-491. doi: 10.1111/dom.13910 pmid: 31696603
[21]	WANG D D, DAY E A, TOWNSEND L K, et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease[J]. Nat Rev Endocrinol, 2021, 17(10):592-607. doi: 10.1038/s41574-021-00529-7 pmid: 34381196
[22]	OVERTON H A, FYFE M T, REYNET C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity[J]. Br J Pharmacol, 2008, 153 (Suppl 1):S76-S81.
[23]	DOLGIN E. Dozens of new obesity drugs are coming: these are the ones to watch[J]. Nature, 2025, 638(8050):308-310.
[24]	ALEXOPOULOS S J, CHEN S Y, BRANDON A E, et al. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice[J]. Nat Commun, 2020, 11(1):2397. doi: 10.1038/s41467-020-16298-2 pmid: 32409697
[25]	中华医学会消化内镜学分会微创减重治疗协作组, 中国医师协会消化医师分会减重专业委员会, 国家消化系统疾病临床医学研究中心(北京). 中国肥胖症消化内镜治疗专家共识[J]. 中华消化内镜杂志, 2024, 41(1):1-10.
	Chinese Society of Gastrointestinal Endoscopy, Chinese Medical Association; Chinese Association of Chief Physicians, Committee of Bariatric Medicine, Branch of Gastrointestinal Physicians; National Clinical Research Center for Digestive Diseases (Beijing). Expert consensus on digestive endoscopic treatment for obesity in China[J]. Chin J Dig Endosc, 2024, 41(1):1-10.
[26]	HANIPAH Z N, SCHAUER P R. Bariatric surgery as a long-term treatment for type 2 diabetes/metabolic syndrome[J]. Annu Rev Med, 2020,71:1-15.
[27]	MELONE S, FERNANDEZ-CEBRIAN J M, AMORES M, et al. Glucose homeostasis improvement after single anastomosis duodenojejunal bypass with sleeve gastrectomy in goto-kakizaki rats[J]. Obes Surg, 35(5):1620-1629.
[28]	SUH H R, MUI J, CHENG E, et al. Outcomes of single anastomosis duodeno ileal bypass and single anastomosis stomach ileal bypass for type Ⅱ diabetes: a systematic review[J]. Expert Rev Endocrinol Metab, 2023, 18(4):337-346.
[29]	VANTANASIRI K, MATAR R, BERAN A, et al. The efficacy and safety of a procedureless gastric balloon for weight loss: a systematic review and meta-analysis[J]. Obes Surg, 2020, 30(9):3341-3346. doi: 10.1007/s11695-020-04522-3 pmid: 32266698
[30]	RAMAI D, SINGH J, MOHAN B P, et al. Influence of the elipse intragastric balloon on obesity and metabolic profile: a systematic review and meta-analysis[J]. J Clin Gastroenterol, 2021, 55(10):836-841. doi: 10.1097/MCG.0000000000001484 pmid: 33394629
[31]	SHARAIHA R Z, HAJIFATHALIAN K, KUMAR R, et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity[J]. Clin Gastroenterol Hepatol, 2021, 19(5):1051-1057.e2.
[32]	NDUMA B N, MOFOR K A, TATANG J, et al. Endoscopic sleeve gastroplasty (ESG) versus laparoscopic sleeve gastroplasty (LSG): a comparative review[J]. Cureus, 2023, 15(7):e41466.
[33]	SHIKORA S A, WOLFE B M, APOVIAN C M, et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReChargeTrial[J]. J Obes, 2015,2015,365604.
[34]	YEN Y A, WANG C C, SUNG W W, et al. Intragastric injection of botulinum toxin A for weight loss: a systematic review and meta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol, 2022, 37(6):983-992.
[35]	NYSTRÖM M, MACHYTKA E, NORÉN E, et al. Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European registry study[J]. Obes Surg, 2018, 28(7):1860-1868. doi: 10.1007/s11695-017-3096-5 pmid: 29388050
[36]	SILVESTRI A, GIL-GOMEZ A, VITALE M, et al. Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and expanding A. muciniphila[J]. Cell Rep Med, 2023, 4(10):101235.
[37]	SCHOUTEN R, RIJS C S, BOUVY N D, et al. A multicenter randomized efficacy study of the endobarrier gastrointestinal liner for presurgical weight loss prior to ba-riatric surgery[J]. Ann Surg, 2010, 251(2):236-243.
[38]	REN M, ZHOU X, YU M, et al. Prospective study of a new endoscopic duodenal-jejunal bypass sleeve in obese patients with nonalcoholic fatty liver disease (with video)[J]. Dig Endosc, 2023, 35(1):58-66.
[39]	RAJAGOPALAN H, CHERRINGTON A D, THOMPSON C C, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study[J]. Diabetes Care, 2016, 39(12):2254-2261. pmid: 27519448
[40]	VAN BAAR A C G, HOLLEMAN F, CRENIER L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study[J]. Gut, 2020, 69(2):295-303. doi: 10.1136/gutjnl-2019-318349 pmid: 31331994
[41]	白洁, 夏泽锋, 陶凯雄. 减重代谢外科技术发展与创新[J]. 中华消化外科杂志, 2024, 23(8):1039-1043.
	BAI J, XIA Z F, TAO K X. Technology development and innovation in bariatric and metabolic surgery[J]. Chin J Dig Surg, 2024, 23(8),1039-1043.
[42]	AKINWANDE O, YUAN F, ABIOLA G O, et al. Angiographic revascularization after bariatric embolization in a swine model[J]. J Vasc Interv Radiol, 2022, 33(6):648-652.e2. doi: 10.1016/j.jvir.2022.02.018 pmid: 35636834
[43]	NUDEL J, BISHARA A M, DE GEUS S W L, et al. Development and validation of machine learning models to predict gastrointestinal leak and venous thromboembolism after weight loss surgery: an analysis of the MBSAQIP database[J]. Surg Endosc, 2021, 35(1):182-191.
[44]	BEKTAŞ M, REIBER B M M, PEREIRA J C, et al. Artificial intelligence in bariatric surgery: current status and future perspectives[J]. Obes Surg, 2022, 32(8):2772-2783.